Drug intelligence / Profile preview

ATX-301

Development stage: Preclinical
Lead developer: Allay Therapeutics
Modality: Small Molecules

Overview

ATX-301 is a small molecule drug developed by Allay Therapeutics for the treatment of pain, specifically within the therapeutic area of nervous system diseases. The drug is currently in preclinical development and has not yet entered clinical trials. Detailed information about its mechanism of action, molecular target, or specific pain indications has not been disclosed publicly as of June 2025. Allay Therapeutics specializes in extended and controlled-release analgesic therapies; however, no further specifics about the pharmacology or delivery method for ATX-301 are available at this time[1][2].

Other names: ATX-301ATX301ATX 301

Beyond the preview

Go deeper on ATX-301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATX-301.

Explore the full profile